The first patient has been dosed in the phase 2 CA-NINE trial comparing TLX250-CDx PET/CT to contrast-enhanced CT for the detection of recurrent ccRCC following surgery. https://lnkd.in/e_YvfnZA
About us
Urology Times takes the lead in providing news analysis of key advances in surgical and non-surgical techniques, treatments, and practice management. Urology Times has been the #1 read publication for more than 20 years, reaching the full universe of physician-specialists treating urologic disorders. We keep urologists up to date so they can quickly provide better patient care while running a more efficient practice.
- Website
-
http://www.UrologyTimes.com
External link for Urology Times
- Industry
- Book and Periodical Publishing
- Company size
- 51-200 employees
- Type
- Public Company
- Specialties
- Urology
Employees at Urology Times
Updates
-
Urology Times reposted this
In this episode of Speaking of Urology, Robert Brannigan, MD, speaks with Juan Andino, MD, MBA, on the recent amendment to the American Urological Association/American Society for Reproductive Medicine - ASRM guideline on male infertility. Urology Times Northwestern Medicine Northwestern University - The Feinberg School of Medicine
Key updates from the AUA/ASRM male infertility guideline amendment
urologytimes.com
-
The first patient has been dosed in the phase 3 UTOPIA trial exploring UGN-103 in patients with low-grade, intermediate-risk NMIBC. https://lnkd.in/eTmXfgvy
Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC
urologytimes.com
-
MIRAGE trial data: Aggressive margin reduction with MRI-guided SBRT significantly reduced late toxicity as well as QOL decrements vs CT-guided SBRT in patients with prostate cancer. | #ASTRO24 Amar Kishan https://lnkd.in/eT72bjpn
MIRAGE trial: Margin reduction with MRI-guided SBRT reduces toxicity vs CT-guided SBRT
urologytimes.com
-
Is hormone therapy safe after prostate cancer radiotherapy? Dr. Alexander Pastuszak of University of Utah School of Medicine discusses the evolving nature of the subject, and how to navigate the decision with patients in our #ASTRO24 interview. Watch here: https://lnkd.in/ekYBNUks
-
Part 2 of our #ASTRO24 interview: Soumyajit Roy, MS, MBBS, of Rush University Medical Center explains how findings showing that 5-year biochemical recurrence status may predict prostate cancer recurrence should alter the clinician-patient interaction. Watch here: https://lnkd.in/e5kwRd3A
-
Data from a retrospective head-to-head analysis showed that apalutamide provided a significant overall survival benefit at 24 months compared with enzalutamide in patients with mCSPC. https://lnkd.in/equKgnZZ
Apalutamide associated with improved survival vs enzalutamide in mCSPC
urologytimes.com
-
Focal dose-escalated salvage high dose rate brachytherapy demonstrated safety and efficacy in patients with radiorecurrent prostate cancer, according to data from the phase 1/2 F-SHARP trial. #ASTRO24 https://lnkd.in/e8Vdf_mZ
Focal salvage HDR brachytherapy appears safe, efficacious in radiorecurrent prostate cancer
urologytimes.com
-
"So far, this is the best evidence talking about natural history of prostate cancer after likely cure versus recurrence.” Dr. Soumyajit Roy of Rush University Medical Center discusses his team's #ASTRO24 abstract that highlights the biochemical-related risk of #ProstateCancer recurrence. Watch: https://lnkd.in/gaka8HBt
-
From #ASTRO24: An interview with GETUG 14 study author Nicolas Demogeot, MD, of the Institut de Cancérologie de Lorraine - ICL, on the clinical evidence supporting high-dose radiation plus short-term ADT to treat intermediate to high risk #ProstateCancer. Read it here: https://lnkd.in/ghu2PwEe